Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Sacubitril-Valsartan in Adults With Congenital Heart Disease
NCT06693674Phase 3Recruiting
- Sponsor
- Mayo Clinic
- Start
- Feb 2025
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacubitril + valsartan in congenital heart disease (CHD), sponsored by Mayo Clinic. Started Feb 2025; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
congenital heart disease (CHD)
Beyond the preview
Go deeper on NCT06693674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06693674.